Cogent Biosciences (NASDAQ:COGT) Shows Perfect Breakout Setup with Top Technical Strength
Cogent Biosciences Inc COGT
$38.93
▼ -5.88%
($-2.43)
⬇️ Below Yest. Low
📅 Earnings This Week
Open
$41.13
Prev Close
$41.36
Day Range
$38.76 – $41.31
52W Range
$10.38 – $43.73
Market Cap
$6.65B
Beta
0.33
EPS (TTM)
$-2.51
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2018-03-29 |
| Shares Out. | 170,870,000 |
| Website | cogentbio.com/ ↗ |
| Phone | 16179455576 |
| Employees | 258 |
| Net Income | -$97.4M |
| Free Cash Flow | -$286.3M |
| Total Assets | $903.0M |
| Total Liabilities | $295.3M |
| Equity | $607.7M |
About Cogent Biosciences Inc
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
Cogent Biosciences Inc is a publicly traded company under the ticker symbol COGT on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
19 analysts (2026-07-01)